Insilico preps first candidate for IND studies, hoping to launch trial in IPF by end of 2021

Max Gelman

Senior Editor

Over the last several years, Alex Zhavoronkov has turned Insilico into one of the most well-connected AI biotechs out there. Now, the Hong Kong-based company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Insilico preps first candidate for IND studies, hoping to launch trial in IPF by end of 2021

Max Gelman

Senior Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Biotech seed rounds sink to lowest level in years as industry slump drags on

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

In­sil­i­co preps first can­di­date for IND stud­ies, hop­ing to launch tri­al in IPF by end of 2021

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Insilico preps first candidate for IND studies, hoping to launch trial in IPF by end of 2021